Please login to the form below

Paul Archer promoted to Chief Commercial Strategy Officer, Envision Pharma Group

Key Appointment News

Horsham, UK, February 21, 2022

Leading global technology-enabled scientific communications company Envision Pharma Group has promoted Paul Archer to Chief Commercial Strategy Officer (CCSO).

In his new role, Archer will lead the development of an integrated commercial group strategy to drive continued revenue growth through service synergies and the implementation of new services. This is a newly defined position that reflects the continued expansion of Envision and its goals of being the global medical affairs partner of choice and to transform the pharma industry, ultimately leading to life-changing outcomes.

Working across the group, Archer will leverage Envision’s unique combination of technology and service capabilities to meet the evolving needs of its medical affairs clients and ensure it continues to lead the way in bringing innovative solutions to the market.

On his appointment that also sees Archer join Envision’s Executive Leadership Team, he said, “I am thrilled to be taking on this role. Envision is full of purpose-driven, talented people who thrive on delivering impactful, often award-winning work for our clients and their patients. I am genuinely excited to be able to apply my 20 years of strategic and commercial experience to drive a successful integrated commercial group for Envision and to realize the opportunities and value this creates for our clients, patients, talent, and Envision as a whole.”

David Thompson, CEO, Envision Pharma Group, added, “Paul has been a strong addition to Envision since he joined a year ago, and he will now lead a growing mandate as Chief Commercial Strategy Officer as we continue to exploit synergies across our four verticals of scientific services, technology, emerging biotech, and value – as well as uncover new service offerings through investment and acquisition that can help us improve our partnership strength with clients.”

--Ends—

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a global, technology-enabled scientific communications company serving pharmaceutical, biotechnology, and medical device companies. As a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) that have applicability across many areas of medical affairs and related functional responsibility, Envision provides scientific communication services and technology solutions to more than 90 companies, including all of the top 20 pharmaceutical companies. Learn more at: www.envisionpharmagroup.com

For further information:

Marsha Caplin
Global Head of Marketing
Envision Pharma Group
Email:
marsha.caplin@envisionpharmagroup.com
Tel: +44 (0)7557 083549

21st February 2022

Share

Company Details

Envision Pharma Group

01403 322 000

Contact Website

Address:
Envision House
5 North Street
Horsham
West Sussex
RH12 1XQ
England

Latest content on this profile

Envision Pharma Group and Alucio™ partner to power next-generation scientific exchange for the life science industry
Collaboration capitalizes on Alucio’s flagship Beacon platform and Envision’s global leadership in medical strategy and healthcare communications
Envision Pharma Group
Envision Pharma Group appoints Head of Envision Value & Access
Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.
Envision Pharma Group
Envision Pharma Group appoints new CEO
Meg Heim named as its new Chief Executive Officer
Envision Pharma Group
Envision Pharma Group partners with scite to display Smart Citations in iEnvision® – the global medical affairs platform
Smart Citations will feature in Library, Datavision®, and Scientific Communication Platform modules
Envision Pharma Group
Envision Pharma Group expands capabilities with specialist behavioral science offering Envision the Change

Envision Pharma Group
Envision Pharma Group and Vitaccess create a global partnership to power evidence generation for the biopharmaceutical industry
Move combines Envision’s global leadership position in medical affairs communications with Vitaccess’ award-winning capabilities in real-world evidence (RWE)
Envision Pharma Group